Heart Disease PET Scan
One of the most important uses of Positron Emission Tomography (PET) technology is its use in diagnosing and treating heart disease. Heart disease is the leading killer of Americans and in 2001 was the cause of 700,142 deaths in the United States of America. The number of non-institutionalized adults diagnosed with heart disease in 2001 was approximately 23 million, which makes up 11.5% of the American population. In examining age group data, cardiovascular death is the leading cause of death for individuals 65 years or older, the second leading killer among the 25 year old to 64 year old age group, the third leading killer among children between the ages of 0 and 14 and was the fifth leading cause of death among individuals between the ages of 15 and 24. Heart disease is also the leading cause of death among American women.About Heart Disease
Heart disease is the leading cause of death in the United States of America and in 2001 was responsible for 700,142 deaths. Heart disease refers to diseases of the heart and the blood vessel system that is contained within the heart. Often associated with heart disease, cardiovascular disease refers to diseases of the heart and diseases of the blood vessel system that is contained within the entire body. The blood vessel system contains such organs as the brains, legs, and lungs.
Heart disease and cardiovascular disease are catchall terms that describe a variety of specific health problems caused by disorders to the heart and the blood vessel systems. To understand the specific type of heart diseases and cardiovascular diseases that are prevalent and the use of PET imaging in their treatment, it is important to understand the different categories of heart and cardiovascular diseases:
Heart disease and cardiovascular disease can occur for a variety of different reasons. Although there are a number of factors that can contribute to heart and cardiovascular disease that cannot be controlled such as aging and family health history, there are a number of risk factors associated with these diseases that can be avoided. Such risk factors include:
Heart disease is a difficult disease to detect in its early stages, as it usually produces no symptoms. Often referred to as a silent killer, heart disease and cardiovascular disease do not produce overt symptoms while in its early stages, although heart disease is a disease that takes many years to develop. There are however some symptoms that is indicative of the possibility of heart disease and cardiovascular disease, and these symptoms include:
In most cases, individuals are alerted to their heart disease through a heart attack or a stroke. The American Heart Association lists these warning signs of a stroke:
Symptoms of a heart attack include:
Positron Emission Tomography is an effective procedure used in the diagnosis and treatment of heart disease in the various medical stages of treatment. PET scans of the heart are one of the most effective imaging tools in diagnosing heart disease. It is particularly effective in detecting coronary heart disease, a condition in which the coronary arteries (the small blood vessels that supply blood and oxygen to the heart) are narrowed due to the buildup of fatty material and atherosclerosis (plaque). Due to the narrowing of the coronary arteries, blood flow to the heart is either slowed and can even stop. The early detection of coronary heart disease and other forms of heart disease is vital as the early treatment of heart disease can prevent heart attack and/or stroke.
Clinical studies have shown that PET imaging is more accurate than other tests such as electrocardiogram (ECG) stress testing, single photon emission computed tomography (SPECT), and the angiogram in detecting coronary heart disease. Whereas these tests often produce “false positive” reports detailing the presence of coronary artery disease in a patient where none exists, PET has a 95% diagnostic accuracy rating in identifying coronary heart disease. This makes Positron Emission Tomography the most reliable noninvasive heart imaging technology available and PET imaging is often used in cases where a suspected “false positive” report has been given by these other tests.
PET imaging is used to detect coronary artery disease as it measures blood flow to the heart. A metabolic imaging test, PET imaging involves the administering of a radioactive tracer that is a combination of a radioisotope (a radioactive compound whose movements are detectable by a PET scanner) with a natural body compound. In heart disease diagnosis, the radioactive tracer used in the Positron Emission Tomography procedure is most commonly Fluorodeoxyglucose (FDG), which combines the natural body compound glucose with the radioisotope Fluorine-18. This radioactive tracer, or radiopharmaceutical, is used in heart disease detection as it measures the body’s metabolic reaction to FDG. In cases where heart muscle is damaged or functioning in an improper fashion because it is ischemic (a condition that indicates lowered blood flow and the lacking of sufficient oxygen to sustain its function), its impaired metabolic action will be shown in the PET scan images.
PET scan imaging for heart diseases are taken in two steps. During the first step, FDG will be administered to the patient while they are in a resting state. The images that are produced from this first PET scan will then be checked with a second PET scan in which the patient is administered with dipyridamole, a drug that produces an effect in the body similar to the effects of strenuous exercise. The effects of dipyridamole on PET imaging is that it allows the PET scan to produce images of the arteries in a state of stress. During the initial PET scan where a patient is at rest, regional myocardial perfusion (pumping of blood through the capillaries to the heart muscle) may be maintained despite severe cases of stenosis (the constriction of a blood vessel or valve in the heart). However, the second PET scan produces images of blood flow in the body while the body is in a period of stress and is able to detect instances of coronary heart disease. This is because coronary arteries exhibit a diminished capacity to increase blood flow compared to normal coronary arteries if it suffers from over 50% stenosis.
Following the PET scan for heart disease, the two images produced by the two stages of PET imaging are compared to examine blood flow through the heart muscle. The comparison between the two PET images helps determine the presence of coronary heart disease by measuring blood flow, under these criteria:
Due to its comprehensive and accurate approach, PET imaging is used to reveal coronary artery disease by detecting impaired blood flow and this test is also used to rule out the presence of coronary artery disease in suspected cases.
Additionally, PET imaging is a highly effective imaging tool used in heart disease diagnosis as it produces images that are less likely to be distorted by conditions of the patient’s body, such as obesity or large breast. By giving physicians a high quality image that solely focuses on the patient’s biochemistry that is not obscured by the patient’s anatomical structure, PET leads to more accurate diagnosis in heart disease cases.PET and Heart Disease Staging
Besides detection, Positron Emission Tomography is highly effective in the treatment of heart disease when it is used during the staging phase. Staging commences following heart disease diagnosis and is used to determine the level of heart disease. The staging component of heart disease is critical as it provides the necessary information for physicians in determining an appropriate medical course of heart disease treatment.
Through PET imaging, a physician is able to determine the presence of a coronary artery disease more efficiently than other screening tests. With a diagnostic accuracy rating of 95%, PET scans prevents the likelihood of unnecessary medical treatment in cases where a “false positive” indicating the presence of coronary heart disease where there is none. Consequently, PET scans are often performed to confirm results given by an electrocardiogram (ECG) and/or single photon emission computed tomography (SPECT) that is suspected to be a “false positive.”
Additionally, Positron Emission Tomography is a valuable procedure that is used to determine whether bypass surgery or transplant is an appropriate medical action following diagnosis. This is because PET is the “gold standard” of imaging tests in determining the viability of heart tissue for revascularization (a surgical procedure that is used to open up blocked blood vessels to improve blood flow to the heart). In most instances, a thallium test is used to measure the presence of live tissue. In the thallium test, radioactive thallium is administered into the blood stream and produces images of the heart that traces blood flow to the heart. The images produced by the thallium test outline areas of the heart where there is severely restricted blood flow. These areas are considered to be dead tissue and are termed non-functional. A heart transplant is recommended based on the images produced by the thallium test in cases where there is an abundance of dead heart tissue.
However, PET imaging is a much more effective imaging tool in determining the presence of dead heart tissue. This is because PET scans are a metabolic imaging tool that not only measures blood flow but also cellular metabolism. In many cases, thallium testing will identify dead tissue that are actually alive but are considered “hibernating tissue.” Hibernating tissue refers to areas of the heart that appear to be dead when judged by blood flow but are actually deprived of oxygenated blood. Once it receives an adequate supply of oxygenated blood, the hibernating tissue can contribute again to muscle contraction. As PET imaging is able to detect the presence of hibernating tissue, it is a vital instrument used by physicians in the heart disease staging process. The use of PET often results in bypass surgery for patients that, if thallium tests alone were used, would have been recommended heart transplant.
Positron Emission Tomography is able to detect the presence of hibernating tissue and, therefore, is the most effective imaging tool in heart disease staging because it is a metabolic imaging tool. PET imaging involves the administering of a radioactive tracer that combines a radioisotope (a radioactive compound whose movements are detectable by a PET scanner) with a natural body compound. In heart disease staging, the radioactive tracer used in PET scanning is usually Fluorodeoxyglucose (FDG), which is a combination of the natural body compound glucose and the radioisotope Flourine-18. This radioactive tracer is effective in heart disease staging as it measures the heart’s metabolic reaction to FDG. Much like thallium testing, Positron Emission Tomography produces images that measure blood flow to the heart. However, in addition to measuring blood flow, PET scanning also measures glucose metabolism. Consequently, hibernating tissue that does not produce any signs in thallium testing appear in PET imaging as these cells also use glucose as an energy source. In this manner, PET scans are able to produce the most accurate reports of dead heart tissue as truly dead heart tissue do not demonstrate glucose metabolism.PET and Heart Disease Follow-Up
The information attained in heart disease diagnosis and staging form the basis for further medical action to treat heart disease. A common treatment used to treat heart disease is coronary artery bypass graft (CABG), which is more commonly known as bypass surgery. In this treatment, a short piece of a blood vessel is removed from another part of the patient’s body to replace the clogged portion of a coronary artery. Another common heart disease treatment is percutaneous transluminal coronary angioplasty (PTCA) or as it is more popularly known, angioplasty. PTCA involves the enlargement of the artery opening that is in danger of becoming blocked by attaching a tiny balloon to the tip of a catheter. This balloon is threaded up through an artery until it reaches the developing blockage. It is then inflated to push the blockage aside and enlarge the artery opening. Additional heart disease treatments, such as beta blockers, may attempt to reduce lipid (blood fat) levels.
Regardless of the type of heart disease treatment, one of the most important components of heart disease treatment is the follow-up procedure that confirms heart health. Positron Emission Tomography is a useful procedure to measure changes in blood flow to confirm the effectiveness of the treatment. A highly sensitive non-invasive diagnostic imaging tool, PET imaging is used to reevaluate blood flow following bypass surgery and angioplasty.
Additionally, PET imaging is used to measure the progression of coronary heart disease and it is a useful measure used to measure the effectiveness of lipid lowering treatments.